Nexium Case Begins To Define Contours Of Actavis Decision

Law360, New York (September 27, 2013, 11:52 AM EDT) -- Recently, a federal judge in Massachusetts largely denied a series of motions seeking dismissal of various “pay-for-delay” claims brought by direct and indirect purchasers involving AstraZeneca PLC's acid reflux drug Nexium. Although certain federal and state claims were trimmed on statute of limitations grounds, U.S. District Judge William Young let stand the core claims of the suit based on the alleged continuing harm flowing from the agreements.

This ruling comes just months after the U.S. Supreme Court's long-awaited decision in Federal Trade Commission v. Actavis, and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.